Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Enzymatic degradation in the digestive tract substantially reduces bioavailability, often to the point where clinical benefits become questionable
It's a preliminary screening step, not a clinical decision
Although -oxidation is impaired in the setting of VPA toxicity, this metabolite has a prolonged elimination half-life and could be responsible for the prolonged coma that is sometimes observed despite the normalization in plasma VPA concentrations [17, 18]
Zero placebo-controlled human studies of dihexa have been published
Cell 63 , 10061020 (2016)
US$ 20.03
US$ 22.45
US$ 27.63
US$ 22.52
